A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index


About Corgentech:

Corgentech Inc. (Nasdaq: CGTK) is a biopharmaceutical company focused on the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF Decoys, which work by blocking the activity of certain genes that are linked to disease. Because abnormal gene expression is a fundamental cause of many diseases, controlling the regulators of these genes—the transcription factors—offers an attractive therapeutic approach. Corgentech is focused on TF Decoys initially for the treatment of cardiovascular disease, inflammatory disease and cancer.

Corgentech has a worldwide collaborative agreement with Bristol-Myers Squibb Company (BMS) for the development and commercialization of Corgentech's E2F Decoy. They also have additional TF Decoys in preclinical development for the treatment of inflammatory diseases and cancer, and have retained all rights to those TF Decoys.


Pipeline Chart for Corgentech (all products)


Phase IIIE2F Decoy Coronary Bypass Graft
Phase I E2F Decoy Arterio-Venous Graft


More on Corgentech:

Home Page

Key Statistics for Corgentech

Basic Chart for Corgentech

Analyst Opinion

Analysts Estimates


Biotech100 Index
· What are the Requirements to be listed in the Biotech100 Index?
· See the Biotech100 List

Sponsored Links

Clinical Trials
· What is a Clinical Trial?
·Phase I ,-- Phase II, -- PhaseIII
·What is Randomized Control?
 What is a Double Blind Experiment?
·What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
· Small Cap Stocks
· Stocks and Bonds
· Biotech100 Index

Careers and Employment
· Biotechnology and Pharmaceutical
· What are the Fastest Growing Careers?




Copyright © 2005 BIOTECH100.COM. All rights reserved.